AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and business outlook with emphasis on AIM's strategic focus on pancreatic cancer.
Presentation details: Wednesday, February 11, 2026 at 1:40 PM EST; registration and current corporate presentation on Ampligen breakthroughs are available.
Positive
- None.
Negative
- None.
News Market Reaction – AIM
In the Feb 6 session, AIM declined 7.32%, reflecting a notable negative market reaction. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 19.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Clinical trial update | Positive | +16.6% | Phase 2 interim data for Ampligen plus Imfinzi in pancreatic cancer. |
| Jan 27 | Rights offering terms | Negative | +0.0% | Amended dates and terms for a planned $12.0M rights offering. |
| Jan 23 | Rights offering launch | Negative | -5.2% | Announcement of rights offering units with preferred stock and warrants. |
| Dec 30 | Stock dividend | Neutral | -4.4% | One-for-1,000 stock dividend and related allocation details. |
| Dec 10 | CEO communication | Neutral | -2.7% | CEO Corner video discussing unmet pancreatic cancer need and Ampligen. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent AIM moves often align with news tone: positive clinical and financing updates saw matching price direction, while communication-focused items like stock dividends and CEO media have sometimes met with negative reactions.
Over the last few months, AIM has combined capital-raising steps with oncology progress. A Feb 5, 2026 Phase 2 interim update in pancreatic cancer coincided with a 16.59% rise. January rights-offering announcements targeted up to $12.0 million and produced mixed reactions. A December stock dividend and a CEO Corner segment on Ampligen drew modest share price declines. Today’s webinar notice continues the pattern of investor outreach around the pancreatic cancer program.
Key Terms
pancreatic cancer medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast on Wednesday, February 11th at 1:40 PM EST
OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.
As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pancreatic cancer.
Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:40 PM EST
Presenter: Thomas K. Equels, MS JD, Chief Executive Officer
Registration Link: Here
See AIM's current corporate presentation: Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation – February 2026
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com